Free triiodothyronine magnetic particle chemiluminescence detection kit and preparation method thereof

By directly coating the T3 analog in the free triiodothyroid thyroid orthogonine magnetic microparticle chemiluminescence detection kit and adding inhibitors or denaturants, the problems of high detection complexity and cost in the prior art are solved, and higher detection accuracy and simplicity.

CN118914574APending Publication Date: 2024-11-08DIASINO LAB CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410954960.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-16
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Among the existing free triiodothyroid (T3) detection methods, the method of coating or labeling T3 analogs is complex and costly, which makes it difficult to control the interference of the binding state T3 on the measurement results and affects the accuracy.

Method used

Free triiodothyrogenine magnetic microparticle chemiluminescence detection kit is used to directly coat T3 analog and add inhibitors or denaturants to the kit to simplify the preparation process, reduce costs, and improve detection accuracy.

Benefits of technology

It has achieved simplified preparation process, reduced costs, improved detection accuracy, reduced interference of thyroglobulin binding, and ensured the high accuracy of the kit.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118914574A_ABST
    Figure CN118914574A_ABST
Patent Text Reader

Abstract

The invention discloses a free triiodothyronine magnetic particle chemiluminescence detection kit and a preparation method thereof. The kit comprises a reagent MP, a reagent AE and a reagent R2, the reagent MP is a solid-phase carrier suspension containing a T3 analogue coating; the reagent AE is a T3 antibody buffer solution containing an acridinium ester label; the reagent R2 is a buffer solution containing an inhibitor or a denaturant. According to the application, a mode of directly coating the T3 analogue with the magnetic particles is adopted, so that the preparation process is simpler, the cost is lower, and the stability is better; an inhibitor or a denaturant is added into the kit, so that the influence of triiodothyronine combined with thyroglobulin on the detection result of the kit is reduced, and the accuracy is higher. The kit in the embodiment can specifically and quantitatively detect the content of free triiodothyronine in a serum sample, and is used for auxiliary diagnosis of thyroid dysfunction diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of chemiluminescent immunoassay, and in particular to a free triiodothyronine magnetic microparticle chemiluminescent detection kit and a preparation method thereof. Background Art

[0002] Triiodothyronine (3,5,3'-triiodothyronine, T3) is an iodine derivative of tyrosine. More than 99% of T3 in plasma is reversibly bound to plasma proteins, mainly to thyroxine binding globulin (TBG), and partly to albumin and prealbumin. Only 0.1%-0.3% of T3 in plasma is free, and only free T3 can enter target cells to exert its effects. FT3 can exert its physiological effects by binding to receptors through cell membranes, so it is the truly active part of thyroid hormones that produce physiological effects, and can more accurately reflect the functional state of the thyroid gland and other effects on human body functions, so the level of FT3 can truly reflect the functional state of the thyroid gland more than T3.

[0003] At present, the method of coating or labeling T3 analogs is mostly used to detect FT3 in samples. In the method of labeling T3 analogs, it is required that the analogs have sufficient chemical similarity with the hormone being tested, that is, the analogs must have the activity of binding to T3 antibodies, and the binding ability should be the same or similar to that of T3 molecules, but they do not have the binding activity with binding proteins such as TBG (thyroxine binding globulin) and THBP, or although they have binding activity, the binding ability is far lower than the ability to bind to T3 antibodies. In addition, in the method of coating T3 analogs, in order to improve the coating efficiency, due to the structural and steric hindrance factors of small molecule antibodies, bovine serum albumin (BSA) or chicken ovalbumin (ova) is usually connected before magnetic beads are coated to make a combination of antigen and macromolecule. This process is relatively cumbersome, costly, and batch differences are difficult to control.

[0004] Therefore, in the process of measuring free T3, the bound T3 interferes with the measurement. The bound part and the free part of T3 in the sample are in a dynamic equilibrium state, and the concentration of T3 in the bound part is much greater than that of the free part. The concentration of T3 bound to the protein is 3000-5000 times the concentration of FT3. During the measurement, the antibody binding to the free T3 will cause a disturbance to this balance, and the system needs to re-establish the balance, that is, the bound T3 must dissociate a part to become free, which results in an increase in the total amount of free hormone. Therefore, those skilled in the art need to reduce the interference of the bound T3 to the measurement to the minimum level during the detection process to improve the accuracy of the kit. Summary of the invention

[0005] The present application aims to solve at least one of the technical problems in the related art to a certain extent. To this end, the purpose of the present application is to propose a free triiodothyronine magnetic microparticle chemiluminescence detection kit and a preparation method, which uses T3 analogs for direct coating, does not require the preparation of T3 antigen derivatives, and has a simpler preparation process and lower costs; uses inhibitors or denaturants to reduce the influence of triiodothyronine bound to thyroglobulin on the detection results of the kit, and has higher accuracy.

[0006] According to the first aspect of the present application, a free triiodothyronine magnetic microparticle chemiluminescence detection kit is proposed, the kit comprising: reagent MP, reagent AE and reagent R2; the reagent MP is a solid phase carrier suspension coated with a T3 analog; the reagent AE is a T3 antibody buffer containing an acridinium ester label; the reagent R2 is a buffer containing an inhibitor or a denaturant.

[0007] In some embodiments, the solid phase carrier coated with a T3 analog is carboxyl magnetic beads.

[0008] In some embodiments, the T3 analog is one of 3,5-diiodo-L-tyrosine, D-3,5-diiodotyrosine, 2-iodo-L-tyrosine or 2-iodo-D-tyrosine.

[0009] In some embodiments, the method further comprises a first diluent for diluting the reagent MP and a second diluent for diluting the reagent AE.

[0010] In some embodiments, the first diluent comprises 50 mM Tris-NaCl at pH 7, 3% BSA, 1% sucrose, 0.1% ProClin TM 300 and 0.1% aminopyrine; wherein the concentration of the carboxyl magnetic beads is 0.1-0.5 mg / mL.

[0011] In some embodiments, the second diluent comprises 50 mM citrate buffer at pH 6.5, 1% BSA, 0.1% ProClin TM 300 and 0.1% aminopyrine; the dilution ratio of acridinium ester marker is 1000-50000:1.

[0012] In some embodiments, the inhibitor is at least one of retinoic acid, all-trans retinoic acid, and 4-hydroxyphenyl retinoic acid, and the denaturing agent is interferon-γ.

[0013] In some embodiments, the concentration of the inhibitor is 0.1-1 mg / mL; the concentration of the denaturant is 0.1-1 mg / mL.

[0014] According to the second aspect of the present application, a method for preparing a free triiodothyronine magnetic particle chemiluminescent detection kit is proposed. The kit described in any of the above embodiments is prepared, comprising:

[0015] Preparation of reagent MP: including washing and activating the solid phase carrier in sequence, and then washing to obtain a treated solid phase carrier; adding the T3 analog after pretreatment to the treated solid phase carrier for coating at room temperature for 3 hours; blocking the coated solid phase carrier with a blocking solution for at least 4 times, each time for at least 10 minutes;

[0016] Preparation of reagent AE: Take T3 antibody and dilute it to a final concentration of 0.1 mg / ml, then add acridinium ester to label the antibody: acridinium ester at a ratio of 10:1, shake and react in the dark for 30 minutes; after terminating the reaction, purify the reaction solution.

[0017] In some embodiments, the T3 analog pretreatment method is: dissolving the T3 analog in dimethyl sulfoxide or dimethyl imide, adding di(sulfosuccinimidyl) suberate, and reacting at room temperature for 30 minutes.

[0018] In some embodiments, the solid phase carrier is activated by adding 10 mg / ml EDC and 10 mg / ml NHS solution to the washed solid phase carrier, and shaking and mixing at room temperature for 30 minutes.

[0019] In some embodiments, the reaction solution purification method is: purifying the reaction solution through a Sephadex G-25 column.

[0020] The present application proposes a free triiodothyronine magnetic microparticle chemiluminescence detection kit and a preparation method, which has the following advantages:

[0021] The present application adopts a method of directly coating T3 analogs with magnetic particles, which does not require the preparation of T3 antigen derivatives, and has a simpler preparation process, lower cost and better stability. Inhibitors or denaturants are added to the test kit. The inhibitors will inhibit the activity of thyroglobulin and prevent the decomposition of thyroglobulin to produce triiodothyronine. The denaturants will denature and inactivate thyroglobulin, reducing the influence of triiodothyronine bound to thyroglobulin on the test results of the test kit, and the accuracy is higher.

[0022] Additional aspects and advantages of the present application will be given in part in the description below, and in part will become apparent from the description below, or will be learned through the practice of the present application. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] The above and / or additional aspects and advantages of the present application will become apparent and easily understood from the following description of the embodiments in conjunction with the accompanying drawings, in which:

[0024] Figure 1 is a flow chart of the preparation of a kit proposed in one embodiment of the present application;

[0025] Figure 2 This is a diagram of the kit proposed in one embodiment of the present application and the kit of Roche detecting clinical samples. DETAILED DESCRIPTION

[0026] The embodiments of the present application are described in detail below, and examples of the embodiments are shown in the accompanying drawings. The embodiments described below with reference to the accompanying drawings are exemplary and are only used to explain the present application, and cannot be understood as limiting the present application. On the contrary, the embodiments of the present application include all changes, modifications and equivalents that fall within the spirit and connotation of the attached claims.

[0027] According to the first aspect of the present application, a free triiodothyronine magnetic particle chemiluminescent detection kit is proposed, which includes: reagent MP, reagent AE and reagent R2; reagent MP is a solid phase carrier suspension coated with a T3 analog; reagent AE is a T3 antibody buffer containing an acridinium ester label; reagent R2 is a buffer containing an inhibitor or a denaturant.

[0028] In some embodiments, the solid phase carrier coated with a T3 analog is a carboxyl magnetic bead, and the T3 analog is one of 3,5-diiodo-L-tyrosine, D-3,5-diiodotyrosine, 2-iodo-L-tyrosine or 2-iodo-D-tyrosine.

[0029] In some embodiments, a first diluent for diluting reagent MP and a second diluent for diluting reagent AE are also included.

[0030] That is, in this embodiment, the kit includes: reagent MP, reagent AE and reagent R2, and a first diluent for diluting reagent MP and a second diluent for diluting reagent AE, wherein the first diluent includes 50 mM Tris-NaCl with a pH of 7, 3% BSA, 1% sucrose, 0.1% ProClin TM 300 and 0.1% aminopyrine; wherein the concentration of carboxyl magnetic beads is 0.1-0.5 mg / mL. The second diluent includes 50 mM citrate buffer with a pH of 6.5, 1% BSA, 0.1% ProClin TM 300 and 0.1% aminopyrine; the dilution ratio of acridinium ester marker is 1000-50000:1.

[0031] In some embodiments, the inhibitor is at least one of retinoic acid, all-trans retinoic acid, and 4-hydroxyphenyl retinoic acid, and the denaturant is interferon-γ, wherein the concentration of the inhibitor is 0.1-1 mg / mL; and the concentration of the denaturant is 0.1-1 mg / mL.

[0032] According to the second aspect of the present application, a method for preparing a free triiodothyronine magnetic particle chemiluminescence detection kit is provided. Figure 1 , preparing the kit in any of the above embodiments, comprising:

[0033] S1: Preparation of reagent MP: including washing and activating the solid phase carrier in sequence, and then washing to obtain a treated solid phase carrier; adding the T3 analog after pretreatment to the treated solid phase carrier for coating at room temperature for 3 hours; blocking the coated solid phase carrier with a blocking solution for at least 4 times, each time for at least 10 minutes;

[0034] S2: Preparation of reagent AE: Take T3 antibody and dilute it to a final concentration of 0.1 mg / ml, then add acridinium ester to label the ratio of antibody: acridinium ester to 10:1, shake and react in the dark for 30 minutes; after terminating the reaction, purify the reaction solution.

[0035] The preparation of reagent MP in S1 includes: washing the solid phase carrier twice with pH7.4, 20mM phosphate buffer and then activating it; the activation method of the solid phase carrier is: adding EDC with a concentration of 10mg / ml and NHS solution with a concentration of 10mg / ml to the washed solid phase carrier in turn, and shaking and mixing at room temperature for 30 minutes; the activated solid phase carrier is washed twice with pH7.4, 20mM phosphate buffer.

[0036] The T3 analog pretreatment method in this embodiment is as follows: dissolve the T3 analog in dimethyl sulfoxide or dimethyl sulfide, add di(sulfosuccinimidyl) suberate, and react at room temperature for 30 minutes. Add the pretreated T3 analog to the activated and cleaned carboxyl magnetic beads, and coat at room temperature for 3 hours. Then, the coated solid phase carrier is blocked at least 4 times with a blocking solution, each time for at least 10 minutes, wherein the blocking solution is composed of Tris-NaCl with a concentration of 50mM and a pH value of 8.0 and a concentration of 3% BSA.

[0037] T3 antibody was taken from S2 and diluted to a final concentration of 0.1 mg / ml with a 50 mM carbonate buffer at pH 9.0, and acridinium ester was added, with a labeled ratio of antibody: acridinium ester of 10:1, and the mixture was shaken slowly and reacted for 30 minutes in the dark; 100 mg / mL lysine was added to the system, and the reaction was carried out in the dark for 30 minutes to terminate the reaction. After the reaction was terminated, the reaction solution was purified by a Sephadex G-25 column to obtain a solution containing acridinium ester-labeled T3 antibody.

[0038] Example 1

[0039] Preparation of MP reagent: Take 10 mg of carboxyl magnetic beads and wash them twice with pH 7.4, 20 mM phosphate buffer, using 2 mL of washing solution each time. Weigh appropriate amounts of EDC and NHS respectively, dissolve them into 10 mg / mL activator with sodium acetate buffer at pH 4.8, take 100 uL of each and add them to the washed carboxyl magnetic beads, and shake and mix at room temperature for 30 minutes. Take 0.1 mg of 3,5-diiodo-L-tyrosine and dissolve it in 100 uL dimethyl sulfoxide (DMSO), then add 100 uL 10 mg / mL di(sulfosuccinimidyl) suberate (BS3), and react at room temperature for 30 minutes. The activated magnetic microparticles are washed twice with pH 7.4, 20 mM phosphate buffer, using 2 mL of washing solution each time. Take the treated T3 analog and add it to the activated and washed carboxyl magnetic beads, then add 1.8 mL of sodium acetate buffer at pH 4.8, and coat at room temperature for 3 hours. After coating, the supernatant was removed and the coated magnetic particles were blocked 4 times with a coating solution consisting of 50 mM Tris-NaCl and 3% BSA, using 2 mL of the blocking solution each time for 10 minutes each time.

[0040] AE reagent preparation process: Take 0.1 mg of specific T3 antibody, dilute it with pH 9.0, 50 mM carbonate buffer to a final concentration of 0.1 mg / ml, add 10 uL of 1 mg / mL acridinium ester, shake slowly, and react for 30 minutes in the dark. Weigh an appropriate amount of lysine and dissolve it in pH 9.0, 50 mM carbonate buffer to 100 mg / mL as the stop solution. Add 100 uL of stop solution to the labeling solution and react for 30 minutes in the dark. The labeled mixture is purified by a dextran gel G-25 column to obtain a solution containing acridinium ester-labeled T3 antibody.

[0041] Preparation of R2 reagent: 4-Hydroxyphenyl retinoic acid (0.2 mg / mL) and interferon-γ (0.2 mg / mL) were dissolved in 20 mM phosphate buffer at pH 7.4 until fully dissolved to prepare R2 reagent.

[0042] Example 2

[0043] Preparation of MP reagent: Take 10 mg of carboxyl magnetic beads and wash them twice with pH 7.4, 20 mM phosphate buffer, using 2 mL of washing solution each time. Weigh appropriate amounts of EDC and NHS respectively, dissolve them into 10 mg / mL activator with sodium acetate buffer at pH 4.8, take 100 uL of each and add them to the washed carboxyl magnetic beads, and shake and mix at room temperature for 30 minutes. Take 0.1 mg of 3,5-diiodo-L-tyrosine and dissolve it in 100 uL dimethyl sulfoxide (DMSO), then add 100 uL 10 mg / mL di(sulfosuccinimidyl) suberate (BS3), and react at room temperature for 30 minutes. The activated magnetic microparticles are washed twice with pH 7.4, 20 mM phosphate buffer, using 2 mL of washing solution each time. Take the treated T3 analog and add it to the activated and washed carboxyl magnetic beads, then add 1.8 mL of sodium acetate buffer at pH 4.8, and coat at room temperature for 3 hours. After coating, the supernatant was removed and the coated magnetic particles were blocked 4 times with a coating solution consisting of 50 mM Tris-NaCl and 3% BSA, using 2 mL of the blocking solution each time for 10 minutes each time. After the blocking was completed, 40 mL of the first dilution solution was added.

[0044] AE reagent preparation process: Take 0.1 mg of specific T3 antibody, dilute it with pH 9.0, 50 mM carbonate buffer to a final concentration of 0.1 mg / ml, add 10 uL of 1 mg / mL acridinium ester, shake slowly, and react in the dark for 30 minutes. Weigh an appropriate amount of lysine and dissolve it in pH 9.0, 50 mM carbonate buffer to 100 mg / mL as the stop solution. Add 100 uL of stop solution to the labeling solution and react in the dark for 30 minutes. The labeled mixture is purified by a dextran gel G-25 column to obtain a solution containing acridinium ester-labeled T3 antibody. This marker is diluted to 5000:1 with the second diluent as the AE reagent.

[0045] Preparation of R2 reagent: 4-Hydroxyphenyl retinoic acid (0.2 mg / mL) and interferon-γ (0.2 mg / mL) were dissolved in 20 mM phosphate buffer at pH 7.4 until fully dissolved to prepare R2 reagent.

[0046] The detection mode of the kit is: 50uL sample, 50uL R2 reagent, 25uL MP reagent and 100uL AE reagent, shake and mix, then react at 37°C for 15 minutes. Wash with cleaning solution 5 times, add 100uL of pre-excitation solution and excitation solution to detect the luminescence value signal. The clinical samples were tested simultaneously with the kit of this embodiment and the kit of Roche, and the correlation equation was: y=0.9808x+0.0025, and the correlation R 2 =0.9931, the results are shown in Table 1 and Figure 2 shown.

[0047] Table 1 Clinical sample test values

[0048] Sample No. Roche test value Luminous value Detection value Sample No. Roche test value Luminous value Detection value 1 2.62 213769 2.62 26 7.57 107513 7.57 2 20.36 40708 18.58 27 3.31 157745 4.51 3 12.65 71887 11.57 28 9.76 84487 9.87 4 4.00 182610 3.54 29 2.15 231652 2.20 5 6.25 93510 8.87 30 10.47 97922 8.43 6 14.14 60897 13.45 31 4.48 158426 4.48 7 5.30 141531 5.30 32 16.95 45967 16.95 8 5.97 129850 5.97 33 2.75 256125 1.73 9 10.09 88365 9.42 34 8.59 96244 8.59 10 4.31 162366 4.31 35 5.74 133675 5.74 11 4.53 155717 4.60 36 13.05 63040 13.05 12 3.76 176379 3.76 37 1.50 255011 1.75 13 5.57 136622 5.57 38 4.82 189608 3.31 14 1.35 296424 1.13 39 5.94 130338 5.94 15 2.69 211045 2.69 40 2.91 202910 2.91 16 2.74 270483 1.49 41 48.32 7537 48.47 17 2.39 223230 2.39 42 4.40 163876 4.25 18 1.93 258650 1.68 43 4.43 159567 4.43 19 4.74 127720 6.10 44 19.33 39049 19.15 20 6.15 126979 6.15 45 5.56 136799 5.56 21 3.47 184673 3.47 46 3.68 147164 5.01 22 7.98 109905 7.37 47 4.82 155080 4.63 23 0.91 322796 0.84 48 1.83 254090 1.76 24 46.08 8972 44.76 49 3.64 179727 3.64 25 3.46 232492 2.18 50 3.38 174083 3.84

[0049] It can be seen from Table 1 that the present application is superior to the kit of Roche. At the same time, the real-time stability of the kit of the present application was investigated. The luminescence value of the kit decreased within 10% after 20 months. The results are shown in Table 2.

[0050]

[0051] The free triiodothyronine magnetic microparticle chemiluminescence detection kit of the present application has the characteristics of simple operation, low cost, good stability, high accuracy, etc., and has good advancement and applicability in clinical practice.

[0052] It should be noted that, in the description of this application, the terms "first", "second", etc. are only used for descriptive purposes and cannot be understood as indicating or implying relative importance. In addition, in the description of this application, unless otherwise specified, the meaning of "plurality" is two or more.

[0053] Any process or method description in a flowchart or otherwise described herein may be understood to represent a module, segment or portion of code that includes one or more executable instructions for implementing the steps of a specific logical function or process, and the scope of the preferred embodiments of the present application includes alternative implementations in which functions may not be performed in the order shown or discussed, including performing functions in a substantially simultaneous manner or in the reverse order depending on the functions involved, which should be understood by technicians in the technical field to which the embodiments of the present application belong.

[0054] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present application. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner.

[0055] Although the embodiments of the present application have been shown and described above, it can be understood that the above embodiments are exemplary and cannot be understood as limitations on the present application. Ordinary technicians in this field can change, modify, replace and modify the above embodiments within the scope of the present application.

Claims

1. Free triiodothyronine magnetic microparticle chemiluminescence detection kit, It is characterized in that The kit comprises: reagent MP, reagent AE and reagent R2; the reagent MP is a solid phase carrier suspension coated with a T3 analog; the reagent AE is a T3 antibody buffer containing an acridinium ester label; and the reagent R2 is a buffer containing an inhibitor or a denaturant.

2. The kit according to claim 1, It is characterized in that The solid phase carrier coated with T3 analogs is carboxyl magnetic beads.

3. The kit according to claim 2, It is characterized in that The T3 analog is one of 3,5-diiodo-L-tyrosine, D-3,5-diiodotyrosine, 2-iodo-L-tyrosine or 2-iodo-D-tyrosine.

4. The kit according to claim 2 or 3, It is characterized in that Also included is a first diluent for diluting the reagent MP and a second diluent for diluting the reagent AE.

5. The kit according to claim 4, It is characterized in that The first diluent includes 50mM Tris-NaCl with a pH of 7, 3% BSA, 1% sucrose, 0.1% ProClin™ 300 and 0.1% aminopyrine; wherein the carboxyl magnetic beads are used at a concentration of 0.1-0.5mg / mL.

6. The kit according to claim 4, It is characterized in that The second diluent includes 50 mM citrate buffer with a pH of 6.5, 1% BSA, 0.1% ProClin™ 300 and 0.1% aminopyrine; the dilution ratio of the acridinium ester marker is 1000-50000:

1.

7. The kit according to claim 6, It is characterized in that The inhibitor is at least one of retinoic acid, all-trans retinoic acid, and 4-hydroxyphenyl retinoic acid; the denaturant is interferon-γ; the concentration of the inhibitor is 0.1-1 mg / mL; the concentration of the denaturant is 0.1-1 mg / mL.

8. Preparation method of free triiodothyronine magnetic microparticle chemiluminescence detection kit, It is characterized in that Preparation of the kit according to any one of claims 1 to 7, comprising: Preparation of reagent MP: including washing and activating the solid phase carrier in sequence, and then washing to obtain a treated solid phase carrier; adding the T3 analog after pretreatment to the treated solid phase carrier for coating at room temperature for 3 hours; blocking the coated solid phase carrier with a blocking solution for at least 4 times, each time for at least 10 minutes; Preparation of reagent AE: Take T3 antibody and dilute it to a final concentration of 0.1 mg / ml, then add acridinium ester to label the ratio of antibody: acridinium ester to 10:1, shake and react in the dark for 30 minutes; after terminating the reaction, purify the reaction solution.

9. The method according to claim 8, It is characterized in that The pretreatment method of T3 analogue is as follows: dissolve the T3 analogue in dimethyl sulfoxide or dimethyl sulfide, add di(sulfosuccinimide) suberate, and react at room temperature for 30 minutes.

10. The method according to claim 9, It is characterized in that The solid phase carrier activation method is: adding EDC with a concentration of 10 mg / ml and NHS solution with a concentration of 10 mg / ml to the cleaned solid phase carrier in sequence, and shaking and mixing at room temperature for 30 minutes; the reaction solution purification method is: purifying the reaction solution through a dextran gel G-25 column.